Articles from Vector Laboratories

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, in partnership with Spatomics, which specializes in developing spatial biology research tools, today presents a poster at AACR detailing a highly sensitive, multiplexed single-cell in situ analysis method that enables simultaneous detection of ten or more protein and glycan targets in the same biological sample.

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, today announced the appointment of Ashley Scholz as Vice President of Marketing. Ashley brings over 16 years of experience in marketing leadership within the medical device, cancer diagnostics, and molecular diagnostics industries.

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, today announced a partnership with Etcembly, a British biotech innovator applying machine learning to inform the development of novel immunotherapies. The collaboration is intended to accelerate the development of improved recombinant antibody therapeutics that leverage Vector’s expertise in antibody development along with data generated by Etcembly’s AI platform, which was shortlisted by a 2024 AI Innovation Awards program.

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, today announced its intention to merge with Absolute Biotech, a unified company of multiple antibody-centric brands. The transaction, which is a milestone in Vector Laboratories’ commitment to better serve life science customers, solidifies its position as a comprehensive supplier of both custom-engineered and catalog antibodies and sophisticated bioconjugation linkers and as a leader in providing deep bioconjugation expertise.

Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, and Navinci Diagnostics, leader of innovative in situ proximity ligation assay-based solutions, today announced that they have signed an agreement. This collaboration aims to develop cutting-edge biomarker discovery tools, allowing detection of specific protein glycosylation in tissue samples for the first time. Product launches are scheduled for 2025.

Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, today announced the acquisition of Quanta BioDesign, the inventor of discrete polyethylene glycol (dPEG®) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications. This most recent acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.

Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling reagents, and Fluoroprobes, a leader in fluorescent probes and dyes. These acquisitions will expand Vector Laboratories’ manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today announced the launch of its novel product Glysite™ Scout Glycan Screening Kits. These immunofluorescence (IF) kits are fully integrated for the detection of glycan expression in tissue sections and will support the ability to profile and characterize complex glycans in biological systems.